Pet Drug Reports

Ingredients

Active ingredient · pooled across combinations

Oxytetracycline Dihydrate: adverse event reports, pooled

4 ingredient sets in reports · 3 FDA-approved applications in the Green Book

387reports naming the ingredient, 2011–20260% of all reports · about 26 a year
18reports, 12 months to March 202624 in the 12 months before
64.7%classed serious, as reportedall reports: 38.6%
42.4%of reports concern cattlehuman exposure 8.8%

Oxytetracycline Dihydrate appears, alone or combined with other ingredients, in 387 reports in FDA's animal adverse event database (May 2011 to January 2026). The figures here pool all 4 ingredient sets that include it.

The Green Book lists 3 FDA-approved applications containing it. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

18 reports arrived in the 12 months to March 2026, down 25% from 24 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. That is about 26 reports a year over its reporting history and 0% of all reports.

Pooled across every set, the terms listed most often are death (17.6%), vials, Damaged (13.7%) and injection site swelling (7.2%). Many drugs combine several ingredients, and many reports list several drugs, so a term on this page may relate to any of them or to none.

Of reports that state seriousness, 64.7% were classed as serious (38.6% across the whole database); 25.1% record a death or euthanasia (6.4% overall). Ingredients used in older or sicker animals, or in anaesthesia and cancer care, carry higher shares for that reason alone.

Ingredient sets that include oxytetracycline dihydrate

Active ingredients recorded for the drugReportsShare of this page's reportsLatest 12 months
Oxytetracycline Dihydrate22056.8%14
Oxytetracycline + Oxytetracycline Dihydrate16542.6%4
Neomycin Sulfate + Oxytetracycline Dihydrate + Oxytetracycline Hydrochloride10.3%0
Oxytetracycline Dihydrate + Oxytetracycline Hydrochloride10.3%0

Ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another"; counts follow sales volume and years on the market. A report can list more than one set, so shares can add to more than 100%.

Signs listed in reports, pooled

share of oxytetracycline dihydrate reports listing the termall reports in the database

  1. Death17.6%68
  2. Vials, Damaged[a product quality report, not a sign in an animal]13.7%53
  3. Injection site swelling[swelling where the injection was given]7.2%28
  4. Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]7.2%28
  5. Lack of efficacy - NOS[the product did not have the expected effect]7.2%28
  6. Anaphylaxis[sudden severe allergic-type reaction]6.2%24
  7. Bottles, Damaged[a product quality report, not a sign in an animal]4.7%18
  8. Injection site pain[pain where the injection was given]4.1%16
  9. Accidental exposure[exposure that was not intended]3.9%15
  10. Color, Abnormal[a product quality report, not a sign in an animal]3.9%15
  11. Containers, Damaged[a product quality report, not a sign in an animal]3.9%15
  12. Containers, Leaking[a product quality report, not a sign in an animal]3.9%15
  13. Anorexia[not eating]2.8%11
  14. Lethargy[unusually tired or inactive]2.6%10
  15. Appearance, Abnormal[a product quality report, not a sign in an animal]2.3%9
  16. Uncoded sign[a sign with no matching dictionary term]2.3%9
  17. Death by euthanasia[the animal was euthanized]2.1%8
  18. Injection site inflammation[inflammation where the injection was given]2.1%8
  19. Collapse NOS[NOS: not otherwise specified]1.8%7
  20. Injection site reaction NOS[reaction nos where the injection was given]1.8%7
  21. No sign[no clinical sign was reported]1.8%7
  22. Product Defect, General[a product quality report, not a sign in an animal]1.8%7
  23. Behavioural disorder NOS[behaviour change, type not specified]1.6%6
  24. Ineffective, antibiotic[legacy FDA term: the product did not have the expected effect (antibiotic)]1.6%6
  25. Injection site bleeding[bleeding where the injection was given]1.6%6
  26. Injection site lump[lump where the injection was given]1.6%6
  27. Localised pain NOS[NOS: not otherwise specified]1.6%6

Pooled across every ingredient set and every report that names the ingredient. One report can list several terms and several drugs; a term here may relate to any of them or to none.

Monthly reports by species, five years

Dog6 · peak 1
Oct 2021: 1May 2022: 1Jul 2022: 1Dec 2022: 1Mar 2023: 1Apr 2023: 12022202320242025
Cat3 · peak 1
Mar 2023: 1Aug 2023: 1Nov 2024: 12022202320242025
Horse8 · peak 2
Jun 2021: 1Apr 2022: 2Nov 2022: 1Dec 2022: 1Aug 2025: 1Oct 2025: 22022202320242025
Other120 · peak 7
Apr 2021: 1May 2021: 2Jun 2021: 2Jul 2021: 2Aug 2021: 4Sep 2021: 3Oct 2021: 4Nov 2021: 3Dec 2021: 4Jan 2022: 4Feb 2022: 1Mar 2022: 1May 2022: 2Jun 2022: 3Jul 2022: 3Aug 2022: 2Sep 2022: 1Oct 2022: 4Nov 2022: 4Dec 2022: 3Jan 2023: 6Feb 2023: 2Mar 2023: 3Apr 2023: 1Jun 2023: 1Jul 2023: 2Aug 2023: 3Oct 2023: 1Nov 2023: 1Dec 2023: 3Jan 2024: 2Feb 2024: 3Mar 2024: 1Apr 2024: 1May 2024: 5Jul 2024: 7Aug 2024: 2Sep 2024: 2Oct 2024: 1Nov 2024: 3Jan 2025: 1Feb 2025: 1Apr 2025: 2May 2025: 1Jun 2025: 1Jul 2025: 2Sep 2025: 1Oct 2025: 2Nov 2025: 3Jan 2026: 32022202320242025

By month of receipt; each panel has its own scale. The newest months are incomplete because FDA posts reports with a delay of three to six months.

028562011: 220112012: 1520122013: 1520132014: 1520142015: 1220152016: 1720162017: 2420172018: 2920182019: 5620192020: 5520202021: 3720212022: 3520222023: 2720232024: 2820242025: 1720252026: 32026

Outcomes, report types and ages

Outcome recorded in the report

Recovered/Normal19.6%76
Recovered with Sequela0.3%1
Ongoing7%27
Died23%89
Euthanized2.1%8
Outcome Unknown25.8%100

What kind of report it was

Safety issue51.7%200
Lack of expected effectiveness9%35
Both safety and lack of expected effectiveness4.7%18
Manufacturing or product defect34.6%134
Other0%0

Species

Cattle42.4%164
Human exposure8.8%34
Dog5.2%20
Horse3.9%15
Goat2.1%8
Cat1.6%6

Age of the animal

Under 1 year14.2%55
1 to 3 years13.2%51
4 to 7 years4.4%17
8 to 11 years1.8%7
12 years and over9.8%38
Age not given56.6%219

Coloured bar: reports naming oxytetracycline dihydrate. Grey bar: all 1,357,245 reports. Outcomes are as stated by the reporter; FDA has not necessarily determined whether any product played a part.

In context

MeasureOxytetracycline DihydrateAll reports
Reports3871,357,245
Latest 12 months against the 12 before-25%-5%
Classed serious, of reports stating it64.7%38.6%
Death or euthanasia recorded, per 1,000 reports250.663.8
Filed as lack of expected effectiveness (wholly or partly)13.7%23%

Shares of reports, not of animals treated: how many animals receive the ingredient is not public. Ingredients used in anaesthesia, cancer care or in old animals carry more serious outcomes in their reports for that reason alone.

FDA-approved products containing oxytetracycline dihydrate (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

Trade nameActive ingredientsSponsorApproved forApplication
Terramycin 100 for Fish; Terramycin 200 for FishOxytetracycline DihydratePhibro Animal Health Corp.—NADA 038-439
Noromycin 300 LAOxytetracycline DihydrateNorbrook Laboratories, Ltd.Cattle, SwineNADA 141-143
Agrimycin 200Oxytetracycline DihydrateHuvepharma EOODCattle, SwineANADA 200-128

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about oxytetracycline dihydrate reports

How many FDA adverse event reports mention oxytetracycline dihydrate?

387 reports through March 2026, 18 of them in the latest 12 months, counting oxytetracycline dihydrate alone and in combinations.

Which brands do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book reference list on this page names approved products containing oxytetracycline dihydrate without any counts.

In which combinations is oxytetracycline dihydrate reported?

Oxytetracycline Dihydrate (56.8% of these reports), Oxytetracycline + Oxytetracycline Dihydrate (42.6% of these reports), Neomycin Sulfate + Oxytetracycline Dihydrate + Oxytetracycline Hydrochloride (0.3% of these reports) and Oxytetracycline Dihydrate + Oxytetracycline Hydrochloride (0.3% of these reports).

What reactions are reported for oxytetracycline dihydrate?

death (17.6%), vials, Damaged (13.7%), injection site swelling (7.2%), lack of efficacy (bacteria) - NOS (7.2%) and lack of efficacy - NOS (7.2%). Shares are of reports naming the ingredient; one report can list several terms.

Which animals are these reports about?

cattle (42.4%), human exposure (8.8%) and dog (5.2%).

Does a high count mean oxytetracycline dihydrate is a problem ingredient?

A count cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." Widely used ingredients collect more reports because more animals receive them.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Ingredient names follow the Green Book; salts and forms are kept as FDA lists them. Drug entries are matched by the active ingredients their unmasked ingredient field discloses. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.